Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

Elizabeth V. Seiverling; Emmy M. Fernanadez; David Adams

Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

Elizabeth V. Seiverling, Emmy M. Fernanadez, David Adams

Department of Dermatology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.

Original language	English (US)
Pages (from-to)	368-369
Number of pages	2
Journal	Journal of drugs in dermatology : JDD
Volume	5
Issue number	4
State	Published - Apr 2006

All Science Journal Classification (ASJC) codes

Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{452422a992f941659d575db3d0b7a05c,

title = "Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.",

abstract = "EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.",

author = "Seiverling, {Elizabeth V.} and Fernanadez, {Emmy M.} and David Adams",

year = "2006",

month = apr,

language = "English (US)",

volume = "5",

pages = "368--369",

journal = "Journal of drugs in dermatology : JDD",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "4",

}

TY - JOUR

T1 - Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

AU - Seiverling, Elizabeth V.

AU - Fernanadez, Emmy M.

AU - Adams, David

PY - 2006/4

Y1 - 2006/4

N2 - EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.

AB - EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.

UR - http://www.scopus.com/inward/record.url?scp=33748913430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748913430&partnerID=8YFLogxK

M3 - Article

C2 - 16673807

AN - SCOPUS:33748913430

SN - 1545-9616

VL - 5

SP - 368

EP - 369

JO - Journal of drugs in dermatology : JDD

JF - Journal of drugs in dermatology : JDD

IS - 4

ER -

Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this